Antibody Drug Conjugate Development
- Benefit from access to Abzena’s wide range of expertise and state-of-the-art facilities to streamline your ADC development program
- Complete target to manufacturing service offering for all ADC components
- Generate a matrix of candidates for ex-vivo assessment before committing to further development
Develop a Matrix
At Abzena we understand that there is no one solution to the development of antibody drug conjugates and that every target brings its own set of challenges to the development process. Abzena can guide you in the development of a matrix of candidates that can be tested to find the ideal ADC for your patients.
Accelerate ADC Development
Abzena’s customised service accelerates the selection of the optimal ADC candidate for your target of interest. Different conjugation and linker technologies, as well as a range of payloads, can be assessed side by side for efficacy allowing the screening of multiple product candidates to optimise your ADC right from the outset.
Abzena’s approach enables you to make informed decisions on all components of the ADC structure so that the optimal candidate is identified for your target of interest in terms of stability, off-target toxicity and efficacy. In addition, you will have peace of mind that the methodologies used to produce the ADC are simple, scalable and reproducible and ultimately suitable for large scale manufacture. Once the optimised ADC has been identified, the chosen candidate can be seamlessly transferred into Abzena’s manufacturing stream, allowing the accelerated production of small batches of non-GMP ADCs.
Working with Abzena
Abzena’s services are tailored for each project to ensure that the objectives are met or exceeded. Experienced project teams are assigned to each study focusing on progressing projects through to results in the minimum amount of time. Our clients widely regard us as professional and attentive partners who deliver quality results.
To get more information, a quote or to schedule a teleconference please contact us.